CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form-please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF <code>_AND_</code> CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126 URL: http://www.jmir.org/2011/4/e126/

doi: 10.2196/jmir.1923 PMID: 22209829

otokuna46@gmail.com アカウントを切り替える

🔀 共有なし

○ 下書きを保存しました

*必須の質問です

Your name *
First Last

Seiki Tokunaga

Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada

RIKEN, Tokyo, Japan

Your e-mail address *

abc@gmail.com

otokuna46@gmail.com

Title of your manuscript * Provide the (draft) title of your manuscript. $\label{thm:condition} \mbox{Home-based cognitive intervention through asking robots questions: A randomized}$ controlled trial Name of your App/Software/Intervention * If there is a short and a long/alternate name, write the short name first and add the long name in brackets. Home-based cognitive intervention through as Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.27913" 回答を入力 Language(s) * What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French") Japanese URL of your Intervention Website or App e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the $\,$ website. If the intervention is a DVD or hardware, you can also link to an Amazon page. 回答を入力 URL of an image/screenshot (optional) 回答を入力 Accessibility * Can an enduser access the intervention presently? access is free and open access only for special usergroups, not open access is open to everyone, but requires payment/subscription/in-app purchases app/intervention no longer accessible ○ その他: Primary Medical Indication/Disease/Condition * e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)" Healthy older adults Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial Scores of global cognitive functioning tests, re

Recommended "Dose" * What do the instructions for users say on how often the app should be used? Approximately Daily Approximately Weekly Approximately Weekly Approximately Wearly 'as needed" ***CP\$: Approx. Percentage of Users (starters) still using the app as recommended after of a nonths unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% ***CP\$: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly. SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed ***CP\$: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted to a journal and after receiving initial reviewer comments submitted to a journal and after receiving initial reviewer comments submitted to a journal and after receiving initial reviewer comments		ibility of the intervention at the participant's home
What do the instructions for users say on how often the app should be used? Approximately Daily Approximately Weekly Approximately Monthly Approximately Yearly *as needed* *###############################	icus	ibility of the intervention at the participant's nome
Approximately Daily Approximately Weekly Approximately Weekly Approximately Weekly 'as needed' ################################		
Approximately Weekly Approximately Monthly Approximately Yearly 'as needed' *###################################	_	
Approximately Monthly Approximately Yearly *as needed* *code: Approx. Percentage of Users (starters) still using the app as recommended after anomalies of unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% *code: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on a statistically significant difference between control and intervention proup vs control on control on statistically significant difference between control and intervention proup vs control on control on statistically significant difference between control and intervention protentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed *code: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted yet - in late draft status, just before submission submitted to a journal and after receiving initial reviewer comments	_	
Approximately Yearly "as needed" ₹Øth: Approx. Percentage of Users (starters) still using the app as recommended after an amonths unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% ₹Øth: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly. SOME primary outcomes were significantly better in intervention group vs control on ostatistically significant difference between control and intervention protentially harmful: control was significantly better than intervention protentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed ₹Øth: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	_	
**as needed" **as needed" **Cottle: Approx. Percentage of Users (starters) still using the app as recommended after of months unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% **Cottle: Overall, was the app/intervention effective? ** yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on ostatistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed **Cottle: Article Preparation Status/Stage ** At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	_	
和pprox. Percentage of Users (starters) still using the app as recommended after a months unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% *** ** Versall, was the app/intervention effective? ** yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status not submitted yet - in late draft status submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	_	
Approx. Percentage of Users (starters) still using the app as recommended after 3 months unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% 91-100% • ### Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed ################################	_	
winknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% → 少他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status not submitted to a journal but not reviewed yet submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	J	tenne:
0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status not submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments		
21-30% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	•	unknown / not evaluated
21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on ostatistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	0-10%
31-40% 41-50% 51-60% 61-70% 71%-80% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	11-20%
41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	21-30%
51-60% 61-70% 71%-80% 81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	31-40%
61-70% 71%-80% 81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	41-50%
71%-80% 81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	51-60%
81-90% 91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	61-70%
91-100% その他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control on statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	71%-80%
マの他: Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	81-90%
Overall, was the app/intervention effective? * yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	91-100%
yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	その他:
yes: all primary outcomes were significantly better in intervention group vs control partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	Ove	rall. was the app/intervention effective? *
partly: SOME primary outcomes were significantly better in intervention group vs control no statistically significant difference between control and intervention potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments		
potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	partly: SOME primary outcomes were significantly better in intervention group vs
potentially harmful: control was significantly better than intervention in one or more outcomes inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	•	
inconclusive: more research is needed その他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	0	potentially harmful: control was significantly better than intervention in one or more
子の他: Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	$\overline{}$	
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	\sim	
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments		C 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments		
not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments		11231 your arrive proparation are you currently (at the time you ill ill this form)
submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments	At w	not submitted yet - in early draft status
submitted to a journal and after receiving initial reviewer comments	At w	
	At w	not submitted yet - in late draft status, just before submission
	At w	not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet

Journal * If you already know where you w provide the journal name (if it is				,	/···
not submitted yet / unclear	where I will	l submit thi:			
Journal of Medical Internet					
JMIR mHealth and UHealth		,			
JMIR Serious Games					
JMIR Mental Health					
JMIR Public Health					
JMIR Formative Research					
Other JMIR sister journal					
○ その他:					
Is this a full powered effective Pilot/feasibility Fully powered	eness trial	or a pilot/f	easibility t	trial? *	
Manuscript tracking number * If this is a JMIR submission, plea (The ms tracking number can be when you login as author in JMIII tracking number is the four-digit each published article in JMIR)	ase provide found in th R. If the pap number at	ne submissi per is alread	on acknow y published he DOI, to I	ledgemen d in JMIR, be found a	t email, or then the ms
on oms number (yet) / not (y その他: http://dx.doi.org			shed in JN	/IIR	
			shed in JN	/IIR	
● その他: http://dx.doi.org	g/10.2196/	/47229		AIR	
● その他: http://dx.doi.org	n/10.2196/ randomize	/47229 d trial in th item 1a? *	e title		xplain the
その他: http://dx.doi.org TITLE AND ABSTRACT 1a) TITLE: Identification as a r 1a) Does your paper address (l.e does the title contain the phrareason under "other") yes	randomize CONSORT ase "Randor very in the eferably used ambigue vention incle "electronic lity" (3-D wr substitute ille" or "small	d trial in the item 1a? * mized Control title "web-base ous terms liques non-w" only if offi orlds). Use product na	e title olled Trial* d" and/or " ke "online" ee b-based ine product online" onl mes with b sstead of "i	mobile" a "virtual", internet co is are user y in the co roader ter	nd/or "interactive". omponents (e.g. d. Use "virtual" ontext of "online rms for the
New York: http://dx.doi.org TITLE AND ABSTRACT 1a) TITLE: Identification as a reason under "other") yes その他: 1a-i) Identify the mode of delivery. Pre "electronic game" in the title. Avo Use "Internet-based" only if Interemail), use "computer-based" or only in the context of "virtual rea support groups". Complement olass of products (such as "mob	randomize CONSORT ase "Randor beferably use old ambigue vention incl "electronic lity" (3-D wr substitute life" or "sma forms.	d trial in the item 1a? * mized Control title "web-base ous terms li ludes non-w " only if offl orlds). Use ' product na art phone" ir	e title olled Trial* d" and/or " ke "online" eb-based ine product online" online online online online of "ii 4	mobile" a ."virtual", internet cots are user y in the coroader terphone"), e	nd/or "interactive". omponents (e.g. d. Use "virtual" ontext of "online rms for the
New York: http://dx.doi.org TITLE AND ABSTRACT 1a) TITLE: Identification as a reason under "other") yes その他: 1a-i) Identify the mode of delivery. Pre "electronic game" in the title. Avo Use "Internet-based" only if Interemail), use "computer-based" or only in the context of "virtual rea support groups". Complement olass of products (such as "mob	randomize CONSORT ase "Randor beferably use old ambigue vention incl "electronic lity" (3-D wr substitute life" or "sma forms.	d trial in the item 1a? * mized Control title "web-base ous terms li ludes non-w " only if offl orlds). Use ' product na art phone" ir	e title olled Trial* d" and/or " ke "online" ee b-based ine product online" onl mes with b sstead of "i	mobile" a ."virtual", internet cots are user y in the coroader terphone"), e	nd/or "interactive". omponents (e.g. d. Use "virtual" ontext of "online rms for the

Does your paper address subitem 1a-i? * Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Home-based cognitive intervention through asking robots questions". 1a-ii) Non-web-based components or important co-interventions in title Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support"). 2 3 4 \circ \circ \circ 0 subitem not at all important 選択を解除 Does your paper address subitem 1a-ii? Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study We have conducted fully offline based intervention, hence this item is not relevant for our study. 1a-iii) Primary condition or target group in the title Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial subitem not at all 0 0 0 essential important 選択を解除 Does your paper address subitem 1a-iii? * Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Home-based cognitive intervention "for healthy older adults" through asking robots questions: A randomized controlled trial 1b) ABSTRACT: Structured summary of trial design, methods, results, and NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status. 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it) subitem not at all 0 0 0 essential important 選択を解除

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study examined the "intervention effect of cognitive training moderated by robots on healthy older adults". "A focus on the feasibility of the intervention at the participant's home was also maintained". Feasibility was evaluated by considering both the dropout rate within the intervention and the number of questions posed during the experiment for each participant.

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important essential
遊択を解除

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were randomized into two groups: the intervention group received sessions where participants listened to photo-integrated stories and "asked questions to the robots" (n=40), and the control group received sessions where participants listened to photo-integrated stories and "only thanked the robots" for confirming participation (n=41).

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5
subitem not at all important

1 2 3 4 5

essential 選択を解除

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We conducted a randomized controlled trial with 81 adults over 65 years of age. "Participants were recruited through postal invitations."

adding it)	mation is r			ort in the	abstract	ins etc.), in what the main , consider
	1	2	3	4	5	
subitem not at all	0	0	0	0		
important	0		0	0	•	essential 選択を解除
Does your paper address st. Copy and paste relevant section quotation marks "like this" to this item by providing addition not applicable/relevant for you. There was no significant intercognitive Status-Japanese (Pstudy successfully concluded feasibility of our approach.	ons from the indicate display information and information are study rention effects. (31), recall the indicate of the indicate	ne manus rect quot tion not i ect on the	es from y n the ms e scores o	your mar , or brief of Teleph al fluency	nuscript), ly explain none Inter tasks. A	or elaborate on why the item is rview for dditionally, our
1b-v) CONCLUSIONS/DISCU Conclusions/Discussions in a the trial is negative (primary o discuss whether negative resu (Note: Only report in the abstr- missing from the main body o	bstract for utcome no ults are attr act what th	negative it change ributable ne main p	trials: Di d), and tl to lack o aper is r	iscuss th he interv of uptake	e primar ention wa and disc	as not used, uss reasons.
	1	2	3	4	5	
subitem not at all important	0	0	0	0	•	essential 選択を解除
Does your paper address su Copy and paste relevant sectic quotation marks "like this" to this item by providing addition not applicable/relevant for you There was "no statistically sign functioning". Although the "fea identified issues that need to b session themes.	ons from the indicate display information and information are study the inficant evices in the information and inficant evices in the information are information and information and information and information are information and information and information and information are information and information and information and information are information and information are information and information and information and information are information and information are information and information and information are information and information and information and information are information and information and information are information and information and information are information and information and information are information are information are information and information are information are information are information and information are informat	ne manus rect quot tion not i dence ind	es from y n the ms dicating i	your mar , or brief nterventi	nuscript), ly explain on benef was dem	or elaborate on why the item is its on cognitive onstrated", we
INTRODUCTION						
	entific bac	kground	and exp	olanatio	n of ratio	onale
2a) In INTRODUCTION: Scie 2a-i) Problem and the type of Describe the problem and the as stand-alone intervention vs particular patient population? other interventions, replace or	of system, type of sys incorpora Goals of th compleme	/solutio stem/sol ated in br ne interve ent other	n ution tha oader he ention, e.	t is objec alth care g., being	et of the s program more cos	study: intended 1? Intended for a st-effective to
INTRODUCTION 2a) In INTRODUCTION: Scie 2a-i) Problem and the type of Describe the problem and the as stand-alone intervention vs particular patient population? other interventions, replace or intervention are provided in "N	of system, type of sys incorpora Goals of th compleme	/solutio stem/sol ated in br ne interve ent other	n ution tha oader he ention, e.	t is objec alth care g., being	et of the s program more cos	study: intended 1? Intended for a st-effective to

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Problem

"Despite these benefits found, we could not accurately identify the components of this intervention program that contribute to the enhancement of verbal fluency [18]".

Solution:

In the present study, we explored the effects of "asking questions" on cognitive functions among healthy older adults, assuming that it would be an important factor of verbal fluency enhancement.

2a-ii) Scientific background, rationale: What is known about the (type of) system Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/ diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5
subitem not at all important

1 2 3 4 5
essential
遊択を解除

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"As merely developing methods to improve performance on specific tasks is not enough to improve cognitive function generally applicable to daily life, intervention strategies that bundle multiple components are being researched [22–25]. However, distinguishing the components to clarify the mechanism underlying the intervention effects and develop more effective intervention methods is also important. In the present study, we explored the effects of "asking questions" on cognitive functions among healthy older adults, assuming that it would be an important factor of verbal fluency enhancement."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study conducted an RCT to collect evidence on the feasibility of asking questions to robots at home and its effect on the cognitive functions of healthy older adults. Our hypothesis is that cognitive function will improve in the intervention group compared to the control group. Additionally, the effects and future improvements of the intervention program are discussed."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Stratified block randomization with a 1:1 allocation was implemented".

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons Does your paper address CONSORT subitem 3b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study This item was not relevant because we did not change the eligibility criteria. 3b-i) Bug fixes, Downtimes, Content Changes Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the $\,$ functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2]. subitem not at all 0 0 0 0 important 選択を解除 Does your paper address subitem 3b-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study This item was not relevant to our paper, because we did not major changes during the intervention. 4a) Eligibility criteria for participants Does your paper address CONSORT subitem 4a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "The eligibility criteria for the trial were (1) age \geq 65 years, (2) Telephone Interview for Cognitive Status-Japanese (TICS-J) score ≥ 33, and (3) complaints of cognitive concern." 4a-i) Computer / Internet literacy Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified. subitem not at all 0 0 essential important 選択を解除 Does your paper address subitem 4a-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Participants were community-dwelling older adults with subjective memory concerns living in an urban city (Wako-shi) in Japan. Participants were recruited with mail. In total, 92 participants were screened for eligibility. The eligibility criteria for the trial were (1) age \geq 65 years, (2) Telephone Interview for Cognitive Status-Japanese (TICS-J) score ≥ 33, and (3) complaints of cognitive concern. The exclusion criteria were as follows: (1) any neurological impairment known to affect the central nervous system, (2) any serious complicating disorder, (3) any history of serious head injury, (4) any disease or medication known to affect the central nervous system, (5) medical history of stroke, and (6) need for care. Therefore this item is not relevant for our study."

4a-ii) Open vs. closed, web-based vs. recruited (online vs. offline), e.g. if this was a purely web-based t intervention or for assessment) participant. In online-only trials, having multiple identities was p cookies, email confirmation, phe	face-to-f , from ar rial, or the , i.e., to w clarify if ossible o	ace asse open ac ere were that degr participa r whethe	ssments cess we face-to-f ee got th ints were	: Mention bsite or f ace com e study t quasi-ar al or logi	n how par rom a clir ponents (eam to kr nonymous stical me	nic, and clarify (as part of the now the s and whether easures (e.g.,
	1	2	3	4	5	
subitem not at all important	0	0	0	0	•	essential
						選択を解除
Does your paper address sub Copy and paste relevant section "like this" to indicate direct quo providing additional information applicable/relevant for your stud "Participants were recruited thro	is from the tes from not in the dy	ne manus your mai ie ms, or	nuscript) briefly ex	, or elabo	rate on th	his item by
4a-iii) Information giving durin Information given during recruit recruitment and in the informed documentation as appendix, seu user self-selection, user expecte	ment. Sp consent also ite	ecify hov procedu m X26), a	res (e.g., as this in	publish t formatio	the inforn	ned consent
	1	2	3	4	5	
subitem not at all important	0	0	0	•	0	essential 選択を解除
Does your paper address sub Copy and paste relevant section 'like this' to indicate direct quot providing additional information applicable/relevant for your stud 'Participants were recruited with	is from these from the inot in the day	ne manus your mai	nuscript)	, or elabo	rate on th	his item by
4b) Settings and locations wh	nere the	data we	re collec	cted		
Does your paper address COI Copy and paste relevant section "like this" to indicate direct quol providing additional information applicable/relevant for your stud All RCT procedures were conduct homes.	is from these from the inot in the day	ne manus your mar ie ms, or	script (inc nuscript) briefly ex	, or elabo xplain wh	rate on the or t	his item by n is not
4b-i) Report if outcomes were Clearly report if outcomes were common in web-based trials) or	(self-)as	sessed tl				
	1	2	3	4	5	
subitem not at all important	•	0	0	0	0	essential
						選択を解除

Does your paper address subitem 4b-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Finally, the participants were asked to answer questionnaires on the last day. " 4b-ii) Report how institutional affiliations are displayed Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results) subitem not at all essential important 選択を解除 Does your paper address subitem 4b-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 回答を入力 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript). subitem not at all 0 0 0 0 essential important 選択を解除 Does your paper address subitem 5-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 回答を入力 5-ii) Describe the history/development process Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results. 2 3 1 4 subitem not at all O O O O essential important 選択を解除

Does your paper address subitem 5-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 回答を入力 5-iii) Revisions and updating Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b). 3 subitem not at all OOO essential important 選択を解除 Does your paper address subitem 5-iii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study We have not major updated during the intervention, therefore this item is not relevant for our study. 5-iv) Quality assurance methods Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable. subitem not at all 0 0 0 0 important 選択を解除 Does your paper address subitem 5-iv? Copy and paste relevant sections from the manuscript (include quotes in quotation marks Filke this' to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 回答を入力 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screencapture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting. 4 subitem not at all \circ essential important 選択を解除

Does your paper address subitem 5-v? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study 回答を入力 5-vi) Digital preservation Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login. subitem not at all 0 0 0 0 essential important 選択を解除 Does your paper address subitem 5-vi? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Our system is developed for native application, therefore this item is not applicable. 5-vii) Access Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi). subitem not at all 0 0 0 0 essential important 選択を解除 Does your paper address subitem 5-vii? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Before the experiment, all the experimental devices were mailed to each participant. The system has been preliminarily set up for each participant, eliminating the need for them to log in to the system. 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and - if computer-mediated communication is a component - whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1]. subitem not at all 0 0 0 0 • essential 選択を解除

Does your paper address subitem 5-viii? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study As merely developing methods to improve performance on specific tasks is not enough to improve cognitive function generally applicable to daily life, intervention strategies that bundle multiple components are being researched [22-25]. However, distinguishing the components to clarify the mechanism underlying the intervention effects and develop more effective intervention methods is also important. In the present study, we explored the effects of "asking questions" on cognitive functions among healthy older adults, assuming that it would be an important factor of verbal fluency enhancement. 5-ix) Describe use parameters Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum. 1 0 0 0 0 subitem not at all essential important 選択を解除 Does your paper address subitem 5-ix? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study The application was designed to display participants' experimental schedules and run them automatically so that participants could participate in the experiment by turning on their tablets and robots at home without cumbersome operations, such as taps and swipes.

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 - generalizability).

subitem not at all \circ essential important 選択を解除

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Finally, the system's operation in home-based experiments was also considered [26]. A delivery and reporting function was implemented in our system so that the experiment administrator could remotely set up each experimental session as scheduled and observe the system report of each session, including the number of utterances and errors

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item

- generalizability).						
	1	2	3	4	5	
subitem not at all important	0	•	0	0	0	essential 選択を解除

Does your paper address subitem 5-xi? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study We also developed an original application that manages participants' experimental schedules and displays photos and experimental time in dialogue sessions (shown in Fig. 3 5-xii) Describe any co-interventions (incl. training/support) Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 - generalizability. 1 2 3 4 subitem not at all 0 0 0 0 essential important 選択を解除 Does your paper address subitem 5-xii? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study On the first day of the experiment, the participants learned how to use the robot and tablets through Zoom. Then, a practice session was conducted via Zoom connected. In addition, two sessions were conducted with the administrator's face hidden so that participants could become familiar with the devices. 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed Does your paper address CONSORT subitem 6a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Our primary concern was to examine the extent to which our intervention program improved cognitive function. The TICS-J [30], recall tests, and verbal fluency tasks [31] were assessed pre- and post-intervention as primary outcomes by well-trained psychologists. 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the guestionnaires were designed/deployed If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9]. 1 2 3 4 5 subitem not at all 0 0 0 0 essential important Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text

回答を入力

:

	logfile anal d be report				netrics a	re important
	1	2	3	4	5	
subitem not at all	0	0	0	•	0	essential
important						選択を解除
Does your paper address so Copy and paste relevant secti			ot text			
Feasibility was evaluated by co the number of questions pose	-		-			ervention and
6a-iii) Describe whether, ho obtained	w, and wh	en quali	tative fe	edback	from pai	rticipants was
Describe whether, how, and w (e.g., through emails, feedbac					pants wa	s obtained
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address C Copy and paste relevant secti "like this" to indicate direct qu providing additional informati	ons from th Jotes from on not in th	ne manu: your mai	script (in nuscript)	, or elabo	orate on t	his item by
applicable/relevant for your st There was no changes to trial		after the	trial com	menced.		
7a) How sample size was o			w the clu	stering b	y care pro	ovides or
		cted att				
centers was addressed 7a-i) Describe whether and calculating the sample size Describe whether and how ex	:	ition was	, tanton in			
centers was addressed 7a-i) Describe whether and calculating the sample size Describe whether and how ex	:	ition was		4	5	
centers was addressed 7a-i) Describe whether and calculating the sample size Describe whether and how ex sample size.	pected attr	2				essential
NPT: When applicable, details centers was addressed 7a-i) Describe whether and calculating the sample size Describe whether and how ex sample size. subitem not at all important	pected attr	2	3			essential 選択を解除

H

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have fully completed the study, so there was no relevant item.

8a) Method used to generate the random allocation sequence NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Stratified block randomization with a 1:1 allocation was implemented.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Subsequently, blocks of size 2 were created and randomized.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Stratified block randomization with a 1:1 allocation was implemented. Participants were stratified into male and female groups and then sorted based on total TICS-J scores. Subsequently, blocks of size 2 were created and randomized. The coding was performed in R. This determined which participants belonged to the intervention or control group. The experimenter assigned participants to the two groups based on this result. The person who conducted the randomization was different from the experimenter and had no information other than ID, TICS-J scores, and gender at the time of randomization. The assessors were blinded to the allocation results.

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The person who conducted the randomization was different from the experimenter and had no information other than ID, TICS-J scores, and gender at the time of randomization. The assessors were blinded to the allocation results.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment 11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering cointerventions (if any). subitem not at all 0 0 0 0 0 essential important 選択を解除 Does your paper address subitem 11a-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not $% \left(1\right) =\left(1\right) \left(1\right) \left$

applicable/relevant for your study

The person who conducted the randomization was different from the experimenter and had no information other than ID, TICS-J scores, and gender at the time of randomization. The assessors were blinded to the allocation results.

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

2 3 subitem not at all OOO essential important 選択を解除

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

回答を入力

11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study examined the intervention effect of cognitive training moderated by robots on healthy older adults. The intervention group and control group have different process, therefore this item is not applicable.

12a) Statistical methods used to compare groups for primary and secondary

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "This study identified no significant intervention effect in category fluency task scores and in letter fluency task scores. 12a-i) Imputation techniques to deal with attrition / missing values Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]). 1 2 3 4 subitem not at all O O O O essential important 選択を解除 Does your paper address subitem 12a-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Additionally, our study successfully concluded with no participant dropouts at follow-up, confirming the feasibility of our approach." 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses Does your paper address CONSORT subitem 12b? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "For the Ancillary analysis, we applied linear mixed models with random intercepts to the intervention group, which included cognitive function scores as outcome variables, time and number of utterances, their interaction terms as explanatory variables, and gender, age, and education as control variables. X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item) X26-i) Comment on ethics committee approval subitem not at all 0 0 0 0 essential important 選択を解除 Does your paper address subitem X26-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The studies involving human participants were reviewed and approved by the RIKEN Ethical Committee (No. Wako3 30-11(6)). All participants provided written informed consent to participate in the study. The studies are registered at Clinical Trials (UMIN000039489)."

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	•	essential			
F 2						選択を解除			
Does your paper address st Copy and paste relevant secti- like this" to indicate direct qu rovviding additional informati- ipplicable/relevant for your st	ons from tl lotes from on not in th	he manu your ma	nuscript)	, or elabo	orate on t	his item by			
(26-iii) Safety and security safety and security procedure he likelihood or detection of I	s, incl. priv	acy cons							
	1	2	3	4	5				
subitem not at all important	0	0	•	0	0	essential			
						選択を解除			
Copy and paste relevant secti- like this" to indicate direct quo providing additional informati- pplicable/relevant for your st	ons from tl lotes from on not in th	he manu your ma	nuscript)	, or elabo	orate on t	his item by			
Copy and paste relevant secti like this" to indicate direct qu providing additional informati applicable/relevant for your st 回答を入力	ons from tl lotes from on not in th	he manu your ma	nuscript)	, or elabo	orate on t	his item by			
Copy and paste relevant sectilike this" to indicate direct quoroviding additional informatical policiable/relevant for your stapplicable/relevant for your stapplicable for each group, the number of care provided intended treatments.	ons from the control of the control	he manu your ma ne ms, or particip re analys enters pe	nuscript) briefly e ants wh sed for t	o were r he prima the inter	andomly ary outco	his item by n is not v assigned, ome			
Does your paper address stops and paste relevant sectifice this to indicate direct quoroviding additional informatical paplicable/relevant for your stops and paste relevant for your stops and paper address to the number of care provand the number of patients to the paste relevant sectification and paste relevant sectifications and paste relevant for your stapplicable/relevant for your stapplicable for your stapp	mbers of t, and wer iders or ceated by ea	particip e analysitem e analysitem e manu your ma	ants wh ants wh sed for t forming orovider	o were r he prima the inter in each c	andomly andomly ary outce vention i center	v assigned, ome n each group			
Copy and paste relevant sectilike this" to indicate direct quoroviding additional informativapplicable/relevant for your staps (Applicable) and the properties of the propert	ons from the content of the content	particip pe analyse e analyse e analyse enters pe ach care	ants wh briefly e ants wh end for t forming provider 13a? * script (in nuscript) briefly e	o were row of the interior row of the row of	andomly ary outce vention i enter	v assigned, ome n each group uotation marks his item by m is not			
Copy and paste relevant sectilike this" to indicate direct quoroviding additional informativapplicable/relevant for your stands and the section of the sect	ons from the control of the control	particip pe analys e manu pour ma pe ms, or particip e analys enters pe he manu pour ma ne ms, or	ants wh ants wh sed for t forming orovider	o were r o were r he prima the inter in each c	andomly any outcome outes in quarte on to the trol group in the an-	v assigned, ome n each group uotation marks his item by m is not			

subitem not at all	1	2	3	4	5	
	0	0	0	0	()	essential
important						選択を解除
Does your paper address si Copy and paste relevant secti applicable (include quotes in our manuscript), or elaborate ns, or briefly explain why the	ons from the quotation ne on this ite	ne manu: narks "lik m by pro	ce this" to	o indicate dditional	e direct q informati	uotes from
4a) Dates defining the per	iods of red	cruitmer	nt and fo	illow-up		
Does your paper address C Copy and paste relevant secti like this" to indicate direct quarroviding additional informati pplicable/relevant for your st All RCT procedures were condomes. "	ons from the lotes from on not in the tudy	ne manu: your mai ie ms, or	script (in nuscript) briefly ex	, or elabo xplain wh	orate on the	his item by n is not
ndicate if critical "secular eve nternet resources available o esources" subitem not at all		in comp	uter hard	lware or I	nternet d 5	elivery
important	O	0	0	0		essential 選択を解除
Does your paper address st Copy and paste relevant sect the time of ti	ons from the notes from on not in the tudy	ne manus your man ne ms, or g the COV	nuscript) briefly ex /ID-19 pa	, or elabo xplain wh andemic;	rate on the or t	his item by n is not e research was
14b) Why the trial ended or	was stopp	oed (ear	ly)			
	ONSORT s	ne manu:	script (in			otation marks

Does your paper address CONSORT subitem 15? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Table 1 shows the baseline characteristics of the participants. 15-i) Report demographics associated with digital divide issues In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ ehealth literacy of the participants, if known. subitem not at all 0 0 0 0 essential important 選択を解除 Does your paper address subitem 15-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "The result that the frequency of device use was positively correlated with the number of questions asked during the intervention, even after controlling for age, gender, and years of education, suggests that future improvements to the usability of our system may enhance intervention effectiveness. ' 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 16-i) Report multiple "denominators" and provide definitions Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention. subitem not at all OOO essential important 選択を解除 Does your paper address subitem 16-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study There were no dropout participants, therefore this item is not relevant for our study. 16-ii) Primary analysis should be intent-to-treat Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i). subitem not at all OOO essential important 選択を解除

Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We conducted a randomized controlled trial with 81 adults over 65 years of age, hence this item is not relevant for our study.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Table 2 shows the results of the linear mixed models used to examine the intervention effects on cognitive function. No significant intervention effects were found for the total TICS-J score, immediate and delayed recall, and verbal fluency. The regression coefficient associated with the time-group interaction term for the category fluency test score was the largest among the study outcomes (1.361), but the effect was not significant (P = .09). Effect sizes f2 < 0.01 for all outcomes."

17a-i) Presentation of process outcomes such as metrics of use and intensity of

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

選択を解除

Does your paper address subitem 17a-i?

subitem not at all

important

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

*The average total number of utterances of the participants in the intervention group was 101.78 (SD = 14.72). The number of utterances was positively correlated with higher letter fluency score at baseline (for letter fluency: B=0.11, SE=0.04, P=.01) while no significant associations were found for the other outcomes (for TICS-J: B=0.03, SE=0.03, P=.30; for category fluency: B= 0.10, SE=0.06, P=.07; for immediate recall: B=-0.01, SE=0.02, P=.64; delayed recall: B=0.01, SE=0.02, P=.55).

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There was no binary outcome, therefore this item is not relevant for our study.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Figure 4 shows the relationship between the digital device use of participants in the intervention group and their total number of utterances.

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

1 2 3 4 5

subitem not at all important important important important

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We have not reported subgroup analysis of comparing only users, hence this item is no relevant for our study.

19) All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no harms or unintended effects in each group, hence this item is no relevant for our study.

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 2 3 4 5
subitem not at all important

1 2 3 4 5
essential 選択を解除

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no severe technical problems, this item is not applicable for our study.

available, on strengths and sh unintended/unexpected effec did or did not use the applicat	ortcoming ts or uses.	s of the a	application udes (if a	on, espec available	ially if the	
	1	2	3	4	5	
subitem not at all	(0	0	\circ	0	
important	Ü				O	essential 選択を解除
Does your paper address si Copy and paste relevant secti "like this" to indicate direct qu providing additional informati applicable/relevant for your si This item is not relevant for ou	ons from the construction on not in the the construction that the construction to the construction to the construction of the	he manu: your mai	nuscript)	, or elabo	rate on t	his item by
DISCUSSION						
22) Interpretation consister considering other relevant of NPT: In addition, take into acc and unequal expertise of care	evidence ount the cl	hoice of	the comp	oarator, la		
22-i) Restate study question starting with primary outco Restate study questions and s primary outcomes and proces	mes and p summarize	orocess the answ	outcom	es (use)		
starting with primary outco Restate study questions and s	mes and p summarize	orocess the answ	outcom	es (use)		
starting with primary outco Restate study questions and s primary outcomes and proces subitem not at all	mes and p summarize ss outcome	the answes (use).	outcom vers sug	es (use) gested by	y the data	
starting with primary outco Restate study questions and s primary outcomes and proces	mes and p summarize ss outcome 1	the answes (use).	outcom vers sug	es (use) gested by	y the data	a, starting with
starting with primary outco Restate study questions and s primary outcomes and proces subitem not at all	mes and psummarize so outcome 1 Ubitem 22 ons from the lotes from on not in the	errocess the answer (use). 2 -i? * he manuaryour mai	outcom wers sug	es (use) gested by 4 Clude qui, or elabo	y the data 5 outes in quarate on t	essential 選択を解除 Jotation marks his item by
starting with primary outco Restate study questions and s primary outcomes and proces subitem not at all important Does your paper address si Copy and paste relevant secti "like this" to indicate direct qu providing additional informati	mes and psummarize sis outcomes a control of the co	rocess the ansves (use). 2 -i? * the manus your maine ms, or fect of as vention i cant inter cant inter the feasil	script (innuscript) briefly esking que nvoled a rotetion bility of ti	es (use) gested by d clude que, or elaboxplain wheelestions to an RCT or effects on the interverse.	y the data 5 otes in quarte on tay the iter improve enducted in scores ention wa	essential 選択を解除 uotation marks his item by n is not cognitive at the of TICS-J, recal s confirmed as
starting with primary outco Restate study questions and s primary outcomes and proces subitem not at all important Does your paper address si Copy and paste relevant secti "like this" to indicate direct qi providing additional informati applicable/relevant for your si "This paper presented the inte function in healthy older adult participant's home. There wer tests, and verbal fluency tasks all participants were able to as	mes and psummarize is outcome is outcome is outcome is outcome in the control of	rocess the answer (use). 2 -i? * the manuaryour mainer ms, or fect of as evention is cant interest the feasilioner quess	outcom vers sug 3 Script (in nuscript) briefly e: bikking que vertion in ev	es (use) gested by description clude que, or elaboxplain wheestions to an RCT or effects on the interversery session future refuture ref	otes in quotes in y the iter improve onducted in scores ention was on, with r	essential 選択を解除 uotation marks his item by n is not cognitive at the of TICS-J, recal s confirmed as
starting with primary outco Restate study questions and s primary outcomes and proces subitem not at all important Does your paper address si Copy and paste relevant secti "like this" to indicate direct qu providing additional informati applicable/relevant for your si "This paper presented the inte function in healthy older adult- participant's home. There were tests, and verbal fluency tasks all participants were able to as dropping out."	mes and psummarize is outcome is outcome is outcome is outcome in the control of	rocess the answer (use). 2 -i? * the manuaryour mainer ms, or fect of as evention is cant interest the feasilioner quess	outcom vers sug 3 Script (in nuscript) briefly e: bikking que vertion in ev	es (use) gested by description clude que, or elaboxplain wheestions to an RCT or effects on the interversery session future refuture ref	otes in quotes in y the iter improve onducted in scores ention was on, with r	essential 選択を解除 uotation marks his item by n is not cognitive at the of TICS-J, recal s confirmed as
starting with primary outco Restate study questions and s primary outcomes and proces subitem not at all important Does your paper address si Copy and paste relevant secti "like this" to indicate direct qu providing additional informati applicable/relevant for your si "This paper presented the inte function in healthy older adult- participant's home. There were tests, and verbal fluency tasks all participants were able to as dropping out."	mes and psummarize sis outcomes a control of the co	rocess the ansves (use). 2 -i? * the manus your mainer ms, or fect of as evention in cant interest the feasilioner questions, s	outcom wers sug 3 Script (in nuscript) briefly e: vention tition in ev	es (use) gested by description clude que, or elabox estions to an RCT coeffects or he interve erry session future re arch.	the data to the sin quarte on to a sorres ention was on, with research	essential 選択を解取 Jotation mark his item by n is not cognitive at the of TICS-J, recs s confirmed a

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Considering this, simply asking questions is not an adequately strong intervention to affect cognitive function, and combining questions with other cognitive elements such as thinking about questions from the other person's point of view or asking questions based on the similarities and differences between one's own thoughts and those of the other person, may be effective in strengthening future interventions."

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

OO subitem not at all 0

important

選択を解除

Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In our study stratified block randomization with a 1:1 allocation was implemented, hence this item is not applicable for our study.

21) Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

subitem not at all important

0 0 0 0

essential

選択を解除

Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"First, this study is limited by the diversity and sample size of the participants. Currently, this program only supports Japanese people; therefore, this study was conducted in an urban city in Japan for feasibility."

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other cointerventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting. subitem not at all 0 0 0 • essential important 選択を解除 Does your paper address subitem 21-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "We also developed an original application that manages participants' experimental schedules and displays photos and experimental time in dialogue sessions (shown in Fig. 3(B)). The application was designed to display participants' experimental schedules and run them automatically so that participants could participate in the experiment by turning on their tablets and robots at home without cumbersome operations, such as taps and swipes." OTHER INFORMATION 23) Registration number and name of trial registry Does your paper address CONSORT subitem 23? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study The studies are registered at Clinical Trials (UMIN000039489) 24) Where the full trial protocol can be accessed, if available Does your paper address CONSORT subitem 24? * Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045027 25) Sources of funding and other support (such as supply of drugs), role of funders Does your paper address CONSORT subitem 25? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "This research was partially supported by JSPS KAKENHI Grant Numbers JP18KT0035. JP19H01138, JP20H05022, JP20H05574, JP20K19471, JP22H04872, and JP22H00544, and the Japan Science and Technology Agency (JPMJCR20G1, JPMJPF2101, and JPMJMS2237)."

X27) Conflicts of Interest (not a CONSORT item)

	1	2	3	4	5	
subitem not at all	0	0	0	0	()	essential
important		Ü	Ü	Ü	Ü	選択を解除
Does your paper address st Copy and paste relevant secti 'like this' to indicate direct qu providing additional informati applicable/relevant for your st	ons from th lotes from on not in th	ne manus your mai	nuscript)	, or elabo	rate on t	his item by
About the CONSORT EHEAL	_TH check	list				
As a result of using this che	ecklist, did	l you ma	ke chan	ges in y	our man	uscript? *
yes, major changes						
yes, minor changes						
O no						
What were the most import checklist?	ant chang	jes you r	made as	a result	of using	g this
回答を入力						
How much time did you spe changes in your manuscrip		ing throu	ugh the o	checklis	t INCLUI	DING making ³
It takes bout 3 business days.						
As a result of using this che	ecklist, do	you thin	k your n	nanuscr	ipt has ir	mproved? *
yes						
O no						
○ その他:						
Would you like to become in This would involve for exampl writing an "Explanation and El	e becomin	g involve	d in parti			
yes						
O no						
○ その他:						選択を解除

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!

Click submit so we have your answers in our database!

送信 フォームをクリア

Google フォームでパスワードを送信しないでください。

このコンテンツは Google が作成または承認したものではありません。 <u>不正行為の報告</u> - <u>利用規約</u> - <u>ブライバシー</u> <u>ポリシー</u>

Google フォーム